Transaction DateRecipientSharesTypePriceValue
6th January 2021Elyse Stock3,750Exercise of derivative$0.00
6th January 2021Elyse Stock1,747Payment by withholding$83.38$145,664.86
6th January 2021James Engelhart3,750Exercise of derivative$0.00
6th January 2021Kimberly Gentile3,750Exercise of derivative$0.00
6th January 2021John Tilton492Payment by withholding$83.38$41,022.96
6th January 2021Kimberly Gentile1,747Payment by withholding$83.38$145,664.86
6th January 2021William A Jr Jones5,000Exercise of derivative$0.00
6th January 2021James Engelhart1,747Payment by withholding$83.38$145,664.86
6th January 2021Elyse Stock1,250Exercise of derivative$0.00
6th January 2021John Tilton1,250Exercise of derivative$0.00
Biohaven Pharmaceutical Holding Company Ltd.
Biohaven Pharmaceutical Holding Company Ltd. logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.


Biohaven Pharmaceutical Holding Co. Ltd. engages in the research and development of late-stage product candidates targeting neurological diseases. It focuses on a pipeline of product candidates that represent mechanistic platforms. The company was founded in 2013 and is headquartered in New Haven, CT.


Ticker: BHVN
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1689813
Employees: 63
Exchange: New York Stock Exchange
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $261 M (0%)
Inventory, Net: $9 M (0%)
Other Assets, Current: $7 M (33%)
Assets, Current: $363 M (10%)
Property, Plant and Equipment, Net: $9 M (10%)
Assets: $424 M (23%)
Accounts Payable, Current: $17 M (21%)
Accrued Liabilities, Current: $118 M (0%)
Liabilities, Current: $166 M (151%)
Other Liabilities, Noncurrent: $5 M (6852%)
Liabilities: $460 M (30%)
Common Stock, Value, Issued: $1 B (36%)
Common Stock, Shares, Issued: $60 M (13%)
Retained Earnings (Accumulated Deficit): $1 B (36%)
Liabilities and Equity: $424 M (23%)
Revenue: $10 M (-10%)
Cost of Revenue: $3 M (-12%)
Gross Margin: $7 M (-9%)
Research and Development: $42 M (-56%)
Operating Income/Loss: $161 M (-48%)
Other Income, net: $20 M (-51%)
Income before taxes: $180 M (-48%)
Provision for income taxes: $658 Th (-51%)